These BRAFV600-mutant patients progressed within 1 year of receiving BRAF inhibitor monotherapy and analysis of the matched pre-treatment and progressing tumours revealed that only the progressing biopsies expressed the BRAF exon 4–8∆ splice variant (Additional file 1: Figure S1). The gene discussed is BRAF; the disease is neoplasm.